Tissue stabilization for heart failure

Inventors

Weldon, Norman R. • Ogle, Matthew F.

Assignees

Nectero Medical Inc • Vatrix CHF Inc

Abstract

Methods and devices for the stabilization of heart tissue to treat congestive heart failure using a therapeutic composition are discussed. The therapeutic composition can comprise an elastin stabilization agent, a collagen stabilization agent, or a combination thereof and be applied to the pericardium, to the outer surface of the myocardium, or a combination thereof using a catheter type of device with an attached reservoir. Controlled placement and release of the therapeutic composition can be achieved using a delivery vehicle to formulate the composition.

Core Innovation

The invention is a method for the stabilization of heart tissue in a living subject. The method comprises applying a therapeutic composition to the pericardium of the living subject, to the outer surface of the myocardium of the living subject, or to a combination of both. The therapeutic composition comprises an elastin stabilization agent, a collagen stabilization agent, or a combination thereof.

The elastin stabilization agent comprises a compound that comprises at least one phenolic hydroxyl group bound to a hydrophobic core. The disclosure includes polyphenolic compounds and derivatives. The collagen stabilization component is described as a photo-activated crosslinking agent or alternatively as an aldehyde with at least two aldehyde groups, a polyamine with carbodiimide, a photo-catalytic dye, genipin, an epoxide, or an azide ester.

The disclosure also emphasizes controlled placement and sustained release using delivery vehicles. Delivery vehicles include in situ gelling hydrogel precursors and/or polymer nanoparticles, including PLGA-based nanoparticles, optionally embedded in hydrogels. The application may be performed using device delivery such as catheter delivery with a reservoir and access port(s), and may include localized wrap or patch delivery for mechanical and chemical stabilization of heart tissue.

Claims Coverage

The independently claimed method includes applying a therapeutic composition to heart tissue locations and defines a composition that includes inventive elastin stabilization and collagen stabilization components. The main inventive feature set comprises application to specified heart tissue sites and the combination of elastin stabilization agents with phenolic hydroxyl group-containing hydrophobic-core compounds and collagen stabilization agents selected from specified photo-activated and crosslinking chemistries.

Overall claim coverage centers on stabilizing heart tissue by applying a therapeutic composition to the pericardium and/or the outer surface of the myocardium, where the composition combines an elastin stabilization agent defined by a phenolic hydroxyl group bound to a hydrophobic core with a collagen stabilization agent selected from photo-activated crosslinking and specified crosslinking chemistries.

Stated Advantages

Documented Applications